Sicklick, Jason K. http://orcid.org/0000-0003-4403-0271
Kato, Shumei
Okamura, Ryosuke http://orcid.org/0000-0001-7352-8621
Schwaederle, Maria
Hahn, Michael E.
Williams, Casey B.
De, Pradip
Krie, Amy
Piccioni, David E.
Miller, Vincent A.
Ross, Jeffrey S.
Benson, Adam
Webster, Jennifer
Stephens, Philip J.
Lee, J. Jack http://orcid.org/0000-0001-5469-9214
Fanta, Paul T.
Lippman, Scott M.
Leyland-Jones, Brian
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Article History
Received: 23 April 2018
Accepted: 22 February 2019
First Online: 22 April 2019
Competing interests
: J.K.S. receives research funds from Foundation Medicine, Inc., Novartis Pharmaceuticals, Blueprint Medicines, and Amgen, as well as consultant fees from Loxo Oncology, Biotheranostics, and Grand Rounds. M.E.H. receives research funds from General Electric and is an equity holder in Illumina, Inc. C.W. receives research support from Takeda, TESARO, and Pfizer, as well as consultant fees from Takeda. V.A.M., J.S.R., and J.W. are employees and equity holders in Foundation Medicine, Inc. V.A.M. is also on the Board of Directors for Revolution Medicines (equity and compensation >$10,000) and has patent royalties for EGFR T790M testing issued to the Memorial Sloan Kettering Cancer Center. A.B. is formerly an employee and is an equity holder in Foundation Medicine, Inc. He is now an employee of Scipher Medicine. P.J.S. is formerly an employee and is formerly an equity holder in Foundation Medicine, Inc. He is now an employee of GRAIL, Inc. J.J.L. served on the Statistical Advisory Board of AbbVie. R.K. has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Grifols, OmniSeq, Foundation Medicine, Inc., Guardant Health, and Konica Minolta, as well as consultant fees from Loxo Oncology, Actuate Therapeutics, Roche, XBiotech, and NeoMed. She serves as an advisor to Soluventis. She receives speaker fees from Roche, and has an equity interest in IDbyDNA, CureMatch, Inc., and Soluventis. All other authors declare no competing interests.